SRRK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SRRK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Scholar Rock Holding's enterprise value is $3,115.86 Mil. Scholar Rock Holding's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00 Mil. Therefore, Scholar Rock Holding's EV-to-Revenue for today is .
The historical rank and industry rank for Scholar Rock Holding's EV-to-Revenue or its related term are showing as below:
During the past 9 years, the highest EV-to-Revenue of Scholar Rock Holding was 132.37. The lowest was -1.76. And the median was 18.65.
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2025-07-08), Scholar Rock Holding's stock price is $35.48. Scholar Rock Holding's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was $0.00. Therefore, Scholar Rock Holding's PS Ratio for today is .
The historical data trend for Scholar Rock Holding's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scholar Rock Holding Annual Data | |||||||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | ||||||||||
EV-to-Revenue | Get a 7-Day Free Trial |
![]() |
89.17 | 37.13 | 6.68 | - | - |
Scholar Rock Holding Quarterly Data | ||||||||||||||||||||
Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | Mar25 | |
EV-to-Revenue | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Scholar Rock Holding's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Scholar Rock Holding's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Scholar Rock Holding's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
Scholar Rock Holding's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 3115.859 | / | 0 | |
= |
Scholar Rock Holding's current Enterprise Value is $3,115.86 Mil.
Scholar Rock Holding's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scholar Rock Holding (NAS:SRRK) EV-to-Revenue Explanation
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
Scholar Rock Holding's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 35.48 | / | 0 | |
= |
Scholar Rock Holding's share price for today is $35.48.
Scholar Rock Holding's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Scholar Rock Holding's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Tracey Sacco | officer: Chief Commercial Officer | 301 BINNEY STREET, 3RD FLOOR, C/O SCHOLAR ROCK HOLDING CORP, CAMBRIDGE MA 02142 |
Erin Moore | other: SVP, Finance | 620 MEMORIAL DRIVE, 2ND FLOOR, 2ND FLOOR, CAMBRIDGE MA 02139 |
Edward H Myles | director | C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451 |
Mo Qatanani | officer: SVP and Head of Research | 301 BINNEY STREET, 3RD FLOOR, C/O SCHOLAR ROCK HOLDING CORP, CAMBRIDGE MA 02142 |
Caryn Parlavecchio | officer: CHRO | SCHOLAR ROCK HOLDING CORPORATION, 301 BINNEY STREET, 3RD FLOOR, CAMBRIDGE MA 02142 |
Junlin Ho | officer: General Counsel | 301 BINNEY STREET, CAMBRIDGE MA 02142 |
Jay T. Backstrom | officer: CEO-Elect | SCHOLAR ROCK HOLDING CORPORATION, 301 BINNEY STREET, 3RD FLOOR, CAMBRIDGE MA 02142 |
Jing L. Marantz | officer: Chief Medical Officer | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Invus Public Equities, L.p. | 10 percent owner | C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022 |
Srinivas Akkaraju | director | 565 EVERETT AVENUE, PALO ALTO CA 94301 |
Samsara Biocapital Gp, Llc | 10 percent owner | 251 CHURCHILL AVENUE, PALO ALTO CA 94301 |
Richard Brudnick | director | BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451 |
Invus Public Equities Advisors, Llc | 10 percent owner | C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022 |
Amaury Wittouck | 10 percent owner | VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L2661 |
Samsara Biocapital, L.p. | 10 percent owner | 628 MIDDLEFIELD ROAD, PALO ALTO CA 94301 |
From GuruFocus
By GuruFocus News • 05-28-2025
By GuruFocus News • 04-23-2025
By GuruFocus News • 05-14-2025
By GuruFocus News • 05-07-2025
By GuruFocus News • 03-21-2025
By Business Wire • 03-17-2025
By GuruFocus News • 05-16-2025
By GuruFocus News • 04-28-2025
By GuruFocus News • 03-25-2025
By Business Wire • 04-18-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.